SiBone (NASDAQ:SIBN - Get Free Report) CEO Laura Francis sold 14,953 shares of SiBone stock in a transaction on Monday, November 16th. The stock was sold at an average price of $23.33, for a total transaction of $348,853.49. Following the transaction, the chief executive officer directly owned 353,176 shares in the company, valued at approximately $8,239,596.08. This represents a 4.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Laura Francis also recently made the following trade(s):
- On Tuesday, November 17th, Laura Francis sold 1,901 shares of SiBone stock. The shares were sold at an average price of $23.18, for a total transaction of $44,065.18.
- On Wednesday, November 4th, Laura Francis sold 75,000 shares of SiBone stock. The shares were sold at an average price of $25.30, for a total transaction of $1,897,500.00.
- On Monday, October 12th, Laura Francis sold 38,006 shares of SiBone stock. The stock was sold at an average price of $20.05, for a total value of $762,020.30.
- On Monday, August 24th, Laura Francis sold 25,972 shares of SiBone stock. The stock was sold at an average price of $20.12, for a total value of $522,556.64.
- On Friday, August 21st, Laura Francis sold 3,923 shares of SiBone stock. The stock was sold at an average price of $20.02, for a total value of $78,538.46.
- On Thursday, August 20th, Laura Francis sold 51,884 shares of SiBone stock. The stock was sold at an average price of $19.46, for a total value of $1,009,662.64.
SiBone Stock Up 1.6%
Shares of SIBN traded up $0.38 on Wednesday, hitting $23.54. The company's stock had a trading volume of 1,120,107 shares, compared to its average volume of 644,914. The company has a quick ratio of 6.15, a current ratio of 7.58 and a debt-to-equity ratio of 0.19. The firm's fifty day moving average price is $20.56 and its 200-day moving average price is $16.85. SiBone has a fifty-two week low of $11.48 and a fifty-two week high of $25.92. The firm has a market capitalization of $1.06 billion, a price-to-earnings ratio of -75.93 and a beta of 0.64.
SiBone (NASDAQ:SIBN - Get Free Report) last announced its quarterly earnings results on Monday, November 2nd. The company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.13) by $0.05. SiBone had a negative net margin of 6.20% and a negative return on equity of 7.57%. The firm had revenue of $55.70 million for the quarter, compared to analyst estimates of $55.31 million. On average, equities research analysts expect that SiBone will post -0.34 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of SIBN. First Light Asset Management LLC lifted its stake in SiBone by 51.8% in the 2nd quarter. First Light Asset Management LLC now owns 8,127,985 shares of the company's stock valued at $132,649,000 after purchasing an additional 2,774,795 shares during the last quarter. Granahan Investment Management LLC increased its position in SiBone by 97.6% during the first quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company's stock worth $21,965,000 after buying an additional 858,942 shares during the last quarter. Paradigm Capital Management Inc. NY increased its position in SiBone by 113.3% during the first quarter. Paradigm Capital Management Inc. NY now owns 1,126,500 shares of the company's stock worth $14,228,000 after buying an additional 598,300 shares during the last quarter. Marshall Wace LLP raised its stake in SiBone by 1.2% in the third quarter. Marshall Wace LLP now owns 698,416 shares of the company's stock valued at $13,130,000 after buying an additional 8,128 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in SiBone by 41.8% in the first quarter. Dimensional Fund Advisors LP now owns 618,939 shares of the company's stock valued at $7,816,000 after buying an additional 182,465 shares during the period. 98.11% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
SIBN has been the topic of a number of recent research reports. Needham & Company LLC dropped their target price on SiBone from $27.00 to $26.00 and set a "buy" rating on the stock in a research report on Tuesday, November 3rd. Wall Street Zen raised SiBone from a "hold" rating to a "buy" rating in a research report on Saturday, November 7th. Truist Financial lifted their price objective on shares of SiBone from $23.00 to $25.00 and gave the company a "buy" rating in a report on Wednesday, October 14th. Weiss Ratings raised shares of SiBone from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, August 20th. Finally, Citigroup reissued a "market outperform" rating on shares of SiBone in a research report on Tuesday, November 3rd. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $25.00.
Get Our Latest Analysis on SiBone
About SiBone
(
Get Free Report)
SI-BONE, Inc. is a medical technology company focused on surgical solutions for conditions affecting the sacroiliac (SI) joint and related pelvic anatomy. Founded in 2008, the company develops implants and instruments used by surgeons in procedures involving the SI joint. Its products include the iFuse Implant System, a minimally invasive approach to SI joint fusion, along with related implant systems designed for SI joint and pelvic fixation procedures. SI-BONE also offers surgical instruments and training resources for healthcare professionals.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider SiBone, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SiBone wasn't on the list.
While SiBone currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.